Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
...
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to ...
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT02566031
- Locations
- 🇰🇷
Novartis Investigative Site, Ulsan, Korea, Republic of
Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 90
- Registration Number
- NCT02546297
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 1060
- Registration Number
- NCT02518139
- Locations
- 🇺🇸
Palmetto Medical Research Associates L.L.C, Easley, South Carolina, United States
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 359
- Registration Number
- NCT02489981
- Locations
- 🇧🇷
Hospital Felício Rocho, Belo Horizonte, Brazil
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-10-16
- Target Recruit Count
- 40
- Registration Number
- NCT02473237
- Locations
- 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico
Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Theron Pharmaceuticals, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02382510
- Locations
- 🇺🇸
Sylvana Research, San Antonio, Texas, United States
🇺🇸WCCT Global, Costa Mesa, California, United States
🇺🇸Dr. Winder & Associates/Toledo Center for Clinical Research, Sylvania, Ohio, United States
Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- University of Crete
- Target Recruit Count
- 200
- Registration Number
- NCT02331940
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7903
- Registration Number
- NCT02296138
- Locations
- 🇺🇸
1237.19.10003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1237.19.10021 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇨🇦1237.19.20021 Boehringer Ingelheim Investigational Site, Moncton, New Brunswick, Canada
A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02275481
- Locations
- 🇺🇸
S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
🇺🇸PMG Research of Wilmington, Wilmington, North Carolina, United States
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 101
- Registration Number
- NCT02263976
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.